ALiEM - Pharm Pearls
NOVEMBER 1, 2023
McGraw-Hill Education; 2019 Madiwale T, Liebelt E. Hypersensitivity reactions to rifampin: Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease.
RX Note
APRIL 16, 2023
External Links Disease Management: A Guide to Clinical Pharmacology, 2016 Rang & Dale’s Pharmacology, 2019 Nonetheless, domperidone should be avoided in patients with conduction disorders or cardiac disease due to its association with Q-T interval prolongation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
RX Note
JANUARY 21, 2023
Adverse Drug Reaction Drug Induced Diseases, 2018 Meyler's Side Effects of Drugs, 2015 Antibiotics The Sanford Guide to Antimicrobial Therapy, 2022 Breastfeeding Briggs' Drugs in Pregnancy and Lactation, 2021 Hale's Medications and Mothers' Milk, 2021 Clinical Practice Applied Therapeutics, 2018 Conn’s Current Therapy, 2022 Current Medical Diagnosis (..)
pharmaphorum
JANUARY 29, 2021
Researchers from the University of East Anglia (UEA) in collaboration with Boots UK and Leiden University analysed 2019 NHS dispensing data across the UK. This would have reduced their risk of side effects and could have led to better clinical outcomes.”. Estimating the potential impact of implementing pre?emptive
pharmaphorum
MARCH 11, 2022
Vraylar, sold in some markets as Reagila, was first approved in 2015 for schizophrenia and bipolar disorder, with its label extended in 2017 to include maintenance treatment of schizophrenia and again in 2019 for bipolar depression.
European Pharmaceutical Review
MAY 2, 2023
In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.
European Pharmaceutical Review
MARCH 11, 2024
As we advance these ultra long-acting options through clinical research and regulatory approval, we will not lose sight of our promise to leave no person living with HIV behind. About the author Sherene Min, MD, MPH, is Vice President of Global Clinical Development at ViiV Healthcare , a role she assumed in October 2019.
Expert insights. Personalized for you.
161 
Let's personalize your content